Solei Announces Application to the OTCQB

ALEXANDRIA, VA / ACCESSWIRE / January 28, 2020 / SOLEI SYSTEMS (OTC PINK:SOLI) a public holding company in the health and wellness field, is pleased to announce its application to the OTCQB Venture Market.

Today the company has initiated a strategy to upgrade its position in the public markets and increase its visibility to a wider range of investors through the process of uplisting to the OTCQB. The company has submitted the OTCQB application materials to OTC Markets Group.

President Josh Flood commented, “Uplisting to OTCQB is a natural milestone in Solei’s growth journey. We are thrilled to further enhance our capabilities to deliver meaningful support services so individuals have better access to quality healthcare. Telemedicine is gaining momentum – and CareClix, Inc., our wholly owned subsidiary, is gaining traction and momentum in this sector.”

The company already meets OTCQB Venture Market compliance requirements by filing audited annual financials prepared in accordance with U.S. GAAP which have been audited by a PCAOB auditor and maintains a Verified Company Profile at OTCMarkets.com.

For more information on Solei Systems, please visit the company’s corporate website at http://www.soleihealth.com Investors wishing to subscribe to the company’s Investor Alert system are asked to fill in the appropriate fields at the bottom of the Investor Relations page to receive notices of S.E.C. filings, press releases after they cross the newswire, periodic newsletters, and other information about Solei Systems’ business that management believes will be of interest to holders of the company’s stock.

About Solei

Solei Systems Inc is a fully reporting, fully audited public holding company in the health and wellness field with its primary focus on telemedicine. Currently, Solei Systems, Inc is comprised of two wholly owned subsidiaries: CareClix, Inc. and Clinical & Herbal Innovations, Inc.

Contact

Solei Systems, Inc
206 N. Washington St. Suite 100
Alexandria, VA 22314
T: (703) 832-4473
www.soleihealth.com

Cautionary Statement Regarding Forward-Looking Information

This press release may contain certain “forward-looking statements” relating to the business of Solei Systems Inc. All statements, other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

SOURCE: Solei Systems, Inc.

View source version on accesswire.com:
https://www.accesswire.com/574343/Solei-Announces-Application-to-the-OTCQB

Staff

Recent Posts

Zepp Health Introduces Zepp OS 4: Redefining Wearable Intelligence by Integrating OpenAI’s GPT-4o into its Amazfit Smartwatches

Amazfit Active becomes the world's first smartwatch under €200 to fully-integrate AI. MILPITAS, Calif., July…

1 hour ago

Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325

Investment will support investigation of Mission's small molecule drug MTX325 in patients with early-stage Parkinson's…

1 hour ago

Clarivate Identifies Six Breakthrough MedTech Trends in 2024 Set to Unlock New Industry Opportunities

New report highlights challenges and opportunities in resilient MedTech industry LONDON, July 2, 2024 /PRNewswire/…

1 hour ago

Poolbeg Pharma PLC Announces Change of Registered Address

Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg'…

4 hours ago

IRLAB’s Phase IIb Study of Pirepemat Can Proceed as Planned after Positive Opinion from External Safety Committee

GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July…

4 hours ago